The oral and IV formulations of delafloxacin (Baxdela, Melinta Therapeutics) for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSIs) caused by designated susceptible bacteria are now available.
With delafloxacin, a fluoroquinolone antibiotic, no dosage adjustments are required for weight, hepatic impairment or mild to moderate renal impairment; there are no food effects; and there is minimal potential for drug interactions.
Approximately 14 million patients